Literature DB >> 31608533

Primary malignant melanoma of the uterine cervix or vagina which were successfully treated with nivolumab.

Mayuka Anko1, Masaru Nakamura1, Yusuke Kobayashi1, Kosuke Tsuji1, Sakura Nakada2, Yoshio Nakamura3, Takeru Funakoshi3, Kouji Banno1, Daisuke Aoki1.   

Abstract

Primary malignant melanomas (MM) originating from the gynecological tract are rare. They respond poorly to immunotherapy when compared with cutaneous MM. This study reports two cases. The first is of a 54-year-old woman with a cervical amelanotic polypoid mass who was diagnosed as having stage IB1 cervical melanoma according to the International Federation of Gynecology and Obstetrics system. At 17 months post-surgery, a computed tomography examination revealed recurrence of a 68 mm pelvic tumor. The second case is of a 37-year-old woman with a 7 cm hemorrhagic mass on the vaginal wall. The patient was diagnosed as having stage IV vaginal melanoma according to the American Joint Committee on Cancer definition. Both patients received nivolumab therapy, programmed cell death receptor 1 monoclonal antibodies, and the tumors almost disappeared. These cases may add the possibility of using colposcopy with narrow-band imaging and positron-emission tomography to diagnose and evaluate primary MM.
© 2019 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  colposcopy; melanoma; nivolumab; uterine cervix; vagina

Year:  2019        PMID: 31608533     DOI: 10.1111/jog.14136

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  7 in total

Review 1.  Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.

Authors:  Fulvio Borella; Mario Preti; Luca Bertero; Giammarco Collemi; Isabella Castellano; Paola Cassoni; Stefano Cosma; Andrea Roberto Carosso; Federica Bevilacqua; Niccolò Gallio; Chiara Benedetto; Leonardo Micheletti
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

2.  Primary vaginal malignant melanoma: A rare case report of successful treatment with nivolumab.

Authors:  Na Guo; Jiawen Zhang
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

3.  Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report.

Authors:  Kenbun Sone; Asako Kukita; Yuri Masui; Daisuke Yamada; Aya Shinozaki-Ushiku; Akira Kawata; Ayumi Taguchi; Yuichiro Miyamoto; Michihiro Tanikawa; Takayuki Iriyama; Mayuyo Mori-Uchino; Tetsushi Tsuruga; Yutaka Osuga
Journal:  Mol Clin Oncol       Date:  2022-01-17

4.  Primary Malignant Melanoma of the Cervix: An Integrated Analysis of Case Reports and Series.

Authors:  Aiping Min; Aizhen Fu; Meiyuan Huang; Hongjing Wang; Huan Chen
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

5.  Primary malignant melanoma of uterine cervix treated with pembrolizumab as adjuvant immunotherapy.

Authors:  Reiko Suzuki; Hiraku Endo; Takamichi Sasaki; Takayoshi Nakamura; Hiroyuki Yamanaka; Shinji Hosonuma; Shiho Kuji; Imari Deura; Tatsuru Ohara; Haruhiro Kondo; Motohiro Chosokabe; Junki Koike; Hiroshi Kadono; Junichi Hasegawa; Nao Suzuki
Journal:  Int Cancer Conf J       Date:  2021-03-08

Review 6.  Current Status and Prospects of Immunotherapy for Gynecologic Melanoma.

Authors:  Mayuka Anko; Yusuke Kobayashi; Kouji Banno; Daisuke Aoki
Journal:  J Pers Med       Date:  2021-05-12

7.  Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina.

Authors:  Christoph Wohlmuth; Iris Wohlmuth-Wieser; Stéphane Laframboise
Journal:  J Low Genit Tract Dis       Date:  2021-04-01       Impact factor: 3.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.